In this interview I addressed how Moderna COVID vaccine differs from other COVID-19 Vaccines, its safety and how resource limited countries improve access.
A community-based opportunistic screening program was implemented to (i) improve
atrial fibrillation (AF) awareness and detection and (ii) assess the performance of the Microlife
WatchBP Home A for detecting AF when used in community screening.
Screening sessions were conducted among people aged ≥ 65 years with no history of AF at public events across Tasmania,
Australia. Participants with positive screening results were referred to their general medical practitioner for assessment. The device’s performance was assessed using the positive predictive value.
A total of 1704 eligible participants were screened at 79 sessions. Of these people, 50 (2.9%) had a
positive screening result. The device correctly identified AF in 22 (46.8%) participants with positive
Results. Among those with subsequently confirmed AF, 6 (27.3%) had a history of AF but were not
aware of the diagnosis, and 16 (72.7%) were identified to have previously undiagnosed AF, with
an overall prevalence of 0.9% (95% CI, 0.58 to 1.52). Oral anticoagulation therapy was initiated in
12 (87.5%) eligible participants. The positive predictive value of the device was 46.8% (95% CI, 33.3 to 60.7).
Given the relatively low performance of the device, its application in community-based opportunistic screening programs for AF is unlikely to be cost-effective.